Form 6-K NeuroSense Therapeutics For: Oct 04

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE MONTH OF OCTOBER 2023

 

COMMISSION FILE NUMBER 001-41084

 

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

 

NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B

Herzliya 4672562 Israel
+972-9-7996183
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On October 4, 2023, NeuroSense Therapeutics Ltd. (the “Company”) issued a press release titled “NeuroSense’s PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model”, announcing the results of a non-sponsored in vitro study of PrimeC in amyotrophic lateral sclerosis (ALS) conducted by Dr. Justin Ichida, PhD at the University of Southern California’s (USC) Stem Cell Ichida Lab. A copy of the press release is filed herewith as Exhibit 99.1

 

This Report on Form 6-K (with respect to exhibit 99.1, only the first three paragraphs) is hereby incorporated by reference into the registrant’s Registration Statements on Form F-3 (File No. 333-269306) and Form S-8 (File No. 333-262480), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit Index

 

Exhibit No.		Description
99.1		Press Release, dated October 4, 2023

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	NeuroSense Therapeutics Ltd.
	By:	/s/ Alon Ben-Noon
		Name:	Alon Ben-Noon
		Title:	Chief Executive Officer

 

Date: October 4, 2023

 

 

2

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE, DATED OCTOBER 4, 2023

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Neurosense Therapeutics' (NRSN) Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
• Watts Water Technologies Named One of “America’s Most Responsible Companies 2024” by Newsweek
• NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023